The Immunomodulatory Nutritional Intervention NR100157 Reduced CD4+ T-Cell Decline and Immune Activation: A 1-Year Multicenter Randomized Controlled Double-Blind Trial in HIV-Infected Persons Not Receiving Antiretroviral Therapy (The BITE Study) | Zendy

Pedro Cahn | Zendy; Kiat Ruxrungtham | Zendy; Brian Gazzard | Zendy; Ricardo Sobhie Diaz | Zendy; Andrea Gori | Zendy; Donald P. Kotler | Zendy; Aldwin J. M. Vriesema | Zendy; Niki Georgiou | Zendy; Johan Garssen | Zendy; Mario Clerici | Zendy; Joep M. A. Lange | Zendy

Open Access

The Immunomodulatory Nutritional Intervention NR100157 Reduced CD4+ T-Cell Decline and Immune Activation: A 1-Year Multicenter Randomized Controlled Double-Blind Trial in HIV-Infected Persons Not Receiving Antiretroviral Therapy (The BITE Study)

Author(s) -

Pedro Cahn,

Kiat Ruxrungtham,

Brian Gazzard,

Ricardo Sobhie Diaz,

Andrea Gori,

Donald P. Kotler,

Aldwin J. M. Vriesema,

Niki Georgiou,

Johan Garssen,

Mario Clerici,

Joep M. A. Lange

Publication year - 2013

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cit171

Subject(s) - medicine , immunology , randomized controlled trial , immune system , human immunodeficiency virus (hiv) , immunopathology , antiretroviral therapy , sida , viral disease , multicenter trial , clinical trial , viral load , multicenter study

The immunomodulatory nutritional product NR100157 was developed for human immunodeficiency virus (HIV)-infected individuals. We hypothesized that targeting the compromised gastrointestinal tract of HIV-infected individuals would result in systemic immunological benefits.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research